| 항목 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.45B | $22.47B | $88.82B | $21.89B | $23.74B | $23.99B | $94.19B | $24.06B |
| Net Income | $4.69B | $2.69B | $14.07B | $11.00B | $5.54B | $5.15B | $26.80B | $5.24B |
| EPS (Diluted) | $1.93 | $1.11 | $5.79 | $4.54 | $2.29 | $2.12 | $11.03 | $2.14 |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospita...
🔗 emfls.github.io 다른 콘텐츠 보기
2026년 8월 11일에 재검토했으며 실시간 시세나 투자 권유가 아닙니다. 수익을 보장하지 않고 원금 손실이 가능하므로 공시 원문과 최신 재무자료를 직접 확인하고 필요하면 인가된 전문가와 상담하세요.